Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Clovis Oncology stock | $5.13
Learn how to easily invest in Clovis Oncology stock.
Clovis Oncology, Inc is a biotechnology business based in the US. Clovis Oncology shares (CLVS) are listed on the NASDAQ and all prices are listed in US Dollars. Clovis Oncology employs 429 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Clovis Oncology
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – CLVS – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
Clovis Oncology stock price (NASDAQ: CLVS)Use our graph to track the performance of CLVS stocks over time.
Clovis Oncology shares at a glance
|Latest market close||$5.13|
|52-week range||$4.08 - $11.10|
|50-day moving average||$5.57|
|200-day moving average||$6.18|
|Wall St. target price||$6.35|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-7.50|
Buy Clovis Oncology shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Clovis Oncology stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Clovis Oncology price performance over time
|1 week (2021-07-20)||N/A|
|1 month (2021-07-01)||-11.55%|
|3 months (2021-04-30)||-13.64%|
|6 months (2021-01-27)||N/A|
|1 year (2020-07-27)||N/A|
|2 years (2019-07-27)||N/A|
|3 years (2018-07-27)||N/A|
|5 years (2016-07-27)||N/A|
Is Clovis Oncology under- or over-valued?
Valuing Clovis Oncology stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Clovis Oncology's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Clovis Oncology's PEG ratio
Clovis Oncology's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.13. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Clovis Oncology's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Clovis Oncology financials
|Revenue TTM||$160 million|
|Gross profit TTM||$128.4 million|
|Return on assets TTM||-30.22%|
|Return on equity TTM||0%|
|Market capitalisation||$507.1 million|
TTM: trailing 12 months
Shorting Clovis Oncology shares
There are currently 28.3 million Clovis Oncology shares held short by investors – that's known as Clovis Oncology's "short interest". This figure is 4.1% up from 27.2 million last month.
There are a few different ways that this level of interest in shorting Clovis Oncology shares can be evaluated.
Clovis Oncology's "short interest ratio" (SIR)
Clovis Oncology's "short interest ratio" (SIR) is the quantity of Clovis Oncology shares currently shorted divided by the average quantity of Clovis Oncology shares traded daily (recently around 6.0 million). Clovis Oncology's SIR currently stands at 4.72. In other words for every 100,000 Clovis Oncology shares traded daily on the market, roughly 4720 shares are currently held short.
However Clovis Oncology's short interest can also be evaluated against the total number of Clovis Oncology shares, or, against the total number of tradable Clovis Oncology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Clovis Oncology's short interest could be expressed as 0.27% of the outstanding shares (for every 100,000 Clovis Oncology shares in existence, roughly 270 shares are currently held short) or 0.2758% of the tradable shares (for every 100,000 tradable Clovis Oncology shares, roughly 276 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Clovis Oncology.
Find out more about how you can short Clovis Oncology stock.
Clovis Oncology share dividends
We're not expecting Clovis Oncology to pay a dividend over the next 12 months.
Clovis Oncology share price volatility
Over the last 12 months, Clovis Oncology's shares have ranged in value from as little as $4.08 up to $11.1. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Clovis Oncology's is 1.6338. This would suggest that Clovis Oncology's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Clovis Oncology overview
Clovis Oncology, Inc. , a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. The company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. It also provides lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3); and FAP-2286, a peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein. The company distributes its products primarily through specialty pharmacies and distributors to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc.
Stocks similar to Clovis Oncology
Clovis Oncology in the news
Clovis: Compelling With Upcoming Catalysts
Will Clovis Oncology (CLVS) Report Negative Earnings Next Week? What You Should Know
Clovis Oncology to Announce Second Quarter 2021 Financial Results and Host Webcast Conference Call on August 4
Frequently asked questionsWhat percentage of Clovis Oncology is owned by insiders or institutions?
Currently 1.836% of Clovis Oncology shares are held by insiders and 49.553% by institutions. How many people work for Clovis Oncology?
Latest data suggests 429 work at Clovis Oncology. When does the fiscal year end for Clovis Oncology?
Clovis Oncology's fiscal year ends in December. Where is Clovis Oncology based?
Clovis Oncology's address is: 5500 Flatiron Parkway, Boulder, CO, United States, 80301 What is Clovis Oncology's ISIN number?
Clovis Oncology's international securities identification number is: US1894641000 What is Clovis Oncology's CUSIP number?
Clovis Oncology's Committee on Uniform Securities Identification Procedures number is: 189464100
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert